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Abstract
The translation of in vitro engineered cardiac tissues (ECTs) from immature
cardiac and stem cell-derived cells toward clinical therapies is benefiting from
the following major advances: (1) rapid progress in the generation of immature
cardiac cells from the cardiac and noncardiac cells of multiple species including
normal and disease human cells, (2) incorporation of multiple cell lineages into
3D tissues, (3) multiple scalable 3D formulations including injectable gels and
implantable tissues, and (4) insights into the regulation of cardiomyocyte prolif-
eration and functional maturation. These advances are based on insights gained
from investigating the regulation of cardiac morphogenesis and adaptation. Our
lab continues to explore this approach, including changes in gene expression that
occur in response to mechanical loading and tyrosine kinase inhibition, the
incorporation of vascular fragments into ECTs, and the fabrication of porous
implantable electrical sensors for in vitro conditioning and postimplantation
testing. Significant challenges remain including optimizing ECT survival post-
implantation and limited evidence of ECT functional coupling to the recipient
myocardium. One clear focus of current research is the optimization and expan-
sion of the cellular constituents, including CM, required for clinical-grade ECTs.
Another major area of investigation will be large animal preclinical models that
more accurately represent human CV failure and that can generate data in
support of regulatory approval for phase I human clinical trials. The generation
of reproducible human ECTs creates the opportunity to develop in vitro
myocardial surrogate tissues for novel drug therapeutics and toxicity assays.
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46.1 Introduction
Following significant cardiac injury, the postnatal human heart lacks the ability to
restore lost myocardium, resulting in an adaptive response that often ultimately
leads to progressive cardiac dysfunction, morbidity, and mortality. There are
currently many strategies for cardiac “cellular therapy” undergoing both preclinical
and clinical trials [1–4]. While there has been modest success with improvement in
cardiac function in some of the early human clinical trials, it is clear that injected or
implanted cells do not survive, and functional improvement occurs via paracrine
mechanisms. In contrast, rapid advances in tissue engineering over the past two
decades have resulted in the generation of functional, multicellular, 3D cardiac
tissues with the potential for translation to human cardiac repair and regeneration
[5–8]. This chapter provides a concise overview of some of the key issues in the
generation, maturation, and translation of these engineered cardiac tissues (ECTs).
46.2 A Broad View of Bioengineering Cardiac Tissues
The bioengineering process for complex tissues begins with an understanding of the
cellular and noncellular constituents of the target tissue [9]. For replacement
myocardium, the major cellular constituents include cardiomyocytes (CM),
fibroblasts, and vessel-associated cells. There are also numerous extracellular
matrix (ECM) constituents including collagen, fibronectin, laminin, and multiple
growth factors bound within the ECM. Of course, the neonatal myocardium and the
adult myocardium have vastly different profiles for cellular and noncellular
constituents, architecture, and biomechanical properties. While all currently suc-
cessful ECTs are constructed using immature cells and simplified ECM
components, the target tissue is usually mature myocardium. The success of ECT
survival, integration, and functional maturation depends on the ability of these ECT
constituents to acquire “mature” fates.
46.3 Immature Cells for Engineered Cardiac Tissues
Because the goal for cardiac regeneration is the restoration of functionally coupled,
working myocardium, a variety of cell sources with the potential to generate CM
are under investigation. Immature CM can be isolated from the hearts of developing
chick, mouse, and rat embryos to generate ECTs for preclinical investigation
(Fig. 46.1) [5–7]. These cells mature in vivo or in vitro along timelines proportional
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to the gestational length of their species of origin. A variety of stem cell sources
(embryonic stem cells, induced pluripotent stem cells, cardiac stem cells, adipose
stem cells, etc.) have also been used to generate immature CM using a variety of
CM lineage specification and selection protocols [10–14]. Not surprisingly, stem
cell populations can be rapidly expanded in vitro along with the induction of cardiac
lineages; however, their functional maturation remains a major technical challenge
[15–17]. Because human cells are required for clinical translation, the optimization
of protocols that can generate large quantities of functional human CM is a high
priority for cardiac repair strategies. Further, there may be advantages to generating
ECTs that contain both cardiac and vascular lineage cells to accelerate angiogenesis
and vascular perfusion of implanted ECTs [11–13].
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Fig. 46.1 Representative engineered cardiac tissues (ECTs) derived from (a) embryonic chick
heart cells; (b) human-iPS-derived cardiomyocytes; (c) embryonic rat heart cells and rat adipose
vascular fragments; and (d) enlarged image of vascular fragments within a rat ECT. Staining for
(a, b) are blue (DAPI, nuclei), green (cardiac troponin T), and red (EdU). Staining for (c, d) are red
(alpha actinin) and green (GFP+vascular fragments). Images (a, c) are 20magnification; images
(b, d) are 40 magnification (Keller lab, unpublished)
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46.4 Various Formulations for Engineered Cardiac Tissues
The constructs used for cardiac tissue repair include the implantation of multicellu-
lar cardiospheres [18], various formulations of 2D cellular sheets [19–22], and
various formulations of 3D tissues [5–8, 13]. The composition of the noncellular
constituents varies from minimal constituents for cardiosphere clusters to a range of
ECM components [23, 24] and growth factors [25–27] selected for their ability to
facilitate CM survival and functional maturation. Some of the ECT formulations
allow for in vitro preconditioning strategies that can stimulate cell proliferation
and/or maturation [5, 6]. While there can be wide variation in the formulation of
ECTs used for preclinical studies, all constituents used to generate ECTs for human
use are required to conform to strict FDA regulatory guidelines that include the
elimination of all sources for potential infectious agents and/or toxins and the
generation of clinical-use materials using good manufacturing practices [28].
46.5 In Vitro ECT Findings
Immature CM survive, proliferate, and functionally mature rapidly within ECTs as
quantified by standard measures of cell number, gene expression profiling
(Fig. 46.2) [29], sarcomeric protein content, electrophysiologic properties, and
the ability to generate substantial force [5–7, 13].
Maturing functional syncytia can include CM, myofibroblasts, and vascular cells
with a functional advantage noted for multiple lineage constructs over pure
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Fig. 46.2 Changes in rat ECT gene expression in response to mechanical loading and/or
p38MAPK inhibition. ECT transcript expression changes at least 1.5-fold measured by microarray
in response to stretch (dark solid bar), the p38MAPK inhibitor BIRB796 (gray solid bar), or
stretch+BIRB796 (dashed bar). Note that most transcripts increased by less than threefold (above
the X-axis) or decreased by less than fivefold (below the X-axis) [29]
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cell proliferation and/or maturation include the use of exogenous paracrine factors
[15, 26], electrical stimulation [17, 27], and/or mechanical conditioning
[6, 13]. Structural CM maturation is readily documented using immunohistochemi-
cal stains for sarcomeric proteins, gap junctions, and the presence of ion channels
[30]. Functional CM maturation is documented by decreasing pacing voltage
thresholds to initiate pacing, intrinsic rates and maximal beat rates in response to
electrical stimulation, increasing rates of electrical conduction across ECTs, devel-
oped force in response to pacing, and both force-length and force-frequency
relations reflecting increased contractility and increased calcium cycling efficiency
(Fig. 46.3). ECTs generated from human-derived cells are now proposed as in vitro
models for human diseases as well as surrogate models to detect drug toxicity prior
to clinical trials [31, 32].
46.6 In Vivo ECT Findings
Ultimately, ECTs require in vivo implantation to assess survival, structural integra-
tion to the recipient myocardium, functional integration, and evidence for recovery
of lost cardiac function. Preclinical implantation models have been primarily small
animals (rodents); however, there is an increasing experience with the preclinical
testing of ECTs using large animal models including pigs [22] and, eventually,
nonhuman primates. The in vivo results have been very encouraging and confirm
the capacity of implanted ECTs to survive, functionally couple, and recover
damaged myocardium within the context of the experimental design [33]. There
are several challenges to the interpretation of in vivo ECT studies. First, many of
the studies involve the implantation of ECTs into immune-compromised animals.
These studies are required to validate the capacity of implanted ECTs to function-
ally couple to recipient myocardium but underestimate the rapid inflammatory
degradation that occurs as evidenced by the presence of macrophage-associated
arginase and reduced ECT post-implant cellularity, even in syngeneic animals
(Fig. 46.4) [13, 30].
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Fig. 46.3 Representative force-frequency relations for chick embryo-derived ECT and human-
iPS-CM-derived ECT. Force-frequency relations quantify force generation in response to
increased beat rate and reflect ECT maturational ability to release and restore Ca2+. Chick embryo
and h-iPS ECT showed increased passive force and reduced active force as beat rate increased
from 120 to 240 bpm consistent with immature Ca2+ release during contraction and limited Ca2+
sequestration at faster rates (Keller lab, unpublished)
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Second, the in vivo results are often reported after relatively short periods that
may not reflect long-term, sustained functional recovery [13]. Finally, the acute
surgical models of cardiac injury in preclinical models often do not fully represent
the human disease state with medical comorbidities and recurrent episodes of
ischemia/injury. To date there are too few studies in large animal models to validate
the feasibility of scaling up CM and ECT production for cardiac repair and to
compare direct cell delivery strategies to ECT implantation strategies for short- and
longer-term efficacy.
46.7 Future Directions
One clear focus of current and future research is the optimization and expansion of
the cellular constituents, including CM, required for clinical-grade ECTs. Ulti-
mately, these cells will need to be from human sources and have minimal immuno-
genic profiles. Another major area of investigation will be large animal preclinical
Fig. 46.4 Representative postimplantation histology for rat embryo-derived ECT implanted onto
the epicardial surface of a syngeneic adult male rat 2 weeks after coronary artery ligation-induced
myocardial infarction. (a) Blue (DAPI, nuclei), (b) red (arginase marker for macrophages), (c)
green (GFP+ for recipient myocardium and inflammatory cells), (d) merged image. Images are
10 magnification. Note the high cellularity of the recipient myocardium (upper left corner) and
the implanted ECT. Note the increased presence of arginase along the outer margins of the
implanted ECT, consistent with the higher cell density noted in ECT (Keller lab, unpublished)
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models that more accurately represent human CV failure and that can generate data
in support of regulatory approval for phase I human clinical trials. Related to these
large animal models will be innovations in the ability to manufacture large-scale
ECTs and to implant them with minimally invasive techniques. Although it is
beyond the scope of this chapter, the generation of reproducible human ECTs
creates the opportunity to develop in vitro myocardial surrogate tissues for novel
drug therapeutics and toxicity assays.
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